Credit: Apellis. Syfovre is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis announced that as part of its investigation into real-world safety ...

More than 100,000 vials have been distributed/administered between real world and clinical trials; since last update, confirmed one additional event of retinal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Apellis is exclusively distributing injection kits with ...

In a preliminary report of its 2025 results, Apellis said that sales of its geographic atrophy (GA) drug Syfovre came in at ...

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of ...

Apellis Pharmaceuticals Inc APLS released a comprehensive update regarding its Syfovre (pegcetacoplan injection) treatment for geographic atrophy (GA) secondary to age-related macular degeneration ...

Apellis Pharmaceuticals, a biotech drug company based in Waltham, Mass., recalled more than 61,000 injection needle kits after eight retinal vasculitis cases were reported. The company is pulling 12 ...

Apellis Pharmaceuticals said Tuesday it is eliminating 25% of its workforce—about 225 jobs—in a restructuring intended to refocus the company’s resources on Syfovre ® (pegcetacoplan injection), its ...

Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in ...